Loss of PL6 protein expression in renal clear cell carcinomas and other VHL-deficient tumours

Journal of Pathology

Volumn 214, Issue 1, 2008, Pages 46-57

  Ivanova, A V ^a,e   Vortmeyer, A ^b   Ivanov, S V ^a,e   Nickerson, M L ^a,c   Maher, E R ^d   Lerman, M I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c TRANSGENOMIC INC   (United States)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CC RCC; Golgi; PL6; Tumour suppressor; VHL

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; VON HIPPEL LINDAU PROTEIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; EMBRYONAL TISSUE; EPITHELIUM CELL; GOLGI COMPLEX; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PL6 GENE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; TUMOR GENE;

BASE SEQUENCE; CARCINOMA, RENAL CELL; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DOWN-REGULATION; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GOLGI APPARATUS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; RNA, MESSENGER; RNA, NEOPLASM; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 38049018934     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2252     Document Type: Article

References (39)

1. Hung J, Kishimoto Y, Sugio K, Virmani A, McIntire DD, Minna JD, et al. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. J Am Med Assoc 1995;273(7):558- 563.
2. Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD, et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999;18(3):643-650.
3. Lerman MI, Minna JD. The 630 kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000;60(21): 6116-6133.
4. Martinez A, Fullwood P, Kondo K, Kishida T, Yao M, Maher ER, et al. Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL-dependent and VHL-independent pathways of tumorigenesis. Mol Pathol 2000;53(3):137-144.
5. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA 2001;98(13):7504-7509.
6. Cohen Y, Singer G, Lavie O, Dong SM, Beller U, Sidransky D. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res 2003;9(8):2981-2984.
7. Senchenko VN, Liu J, Loginov W, Bazov I, Angeloni D, Seryogin Y, et al. Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 2004;23(34):5719-5728.
8. Wasserman JD, Urban S, Freeman M. A family of rhomboid-like genes: Drosophila rhomboid-1 and roughoid/rhomboid-3 cooperate to activate EGF receptor signalling. Genes Dev 2000;14(13):1651-1663.
9. Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE, et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998;95(21):12596-12601.
10. Salnikow K, Blagosklonny MV, Ryan H, Johnson R, Costa M. Carcinogenic nickel induces genes involved with hypoxic stress. Cancer Res 2000;60(1):38-41.
11. Bachert C, Lee TH, Linstedt AD. Lumenal endosomal and Golgi-retrieval determinants involved in pH-sensitive targeting of an early Golgi protein. Mol Biol Cell 2001;12(10):3152-3160.
12. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7(1):85-90.
13. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2(9):673-682.
14. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399(6733): 271-275.
15. Melmon KL, Rosen SW. Lindau's disease: review of literature and study of a large kindread. Am J Med 1964;36:595-617.
16. Choyke PL, Glenn GM, Wagner JP, Lubensky IA, Thakore K. Zbar B, et al. Epididymal cystadenomas in von Hippel-Lindau disease. Urology 1997;49(6):926-931.
17. Glasker S, Tran MG, Shively SB, Ikejiri B, Lonser RR, Maxwell PH, et al. Epididymal cystadenomas and epithelial tumourlets: effects of VHL deficiency on the human epididymis. J Pathol 2006;210(1):32-41.
18. Palade G. Intracellular aspects of the process of protein synthesis. Science 1975;189(4200):347-358.
19. Bivona TG, Philips MR. Ras pathway signalling on endomembranes. Curr Opin Cell Biol 2003;15(2):136-142.
20. Preisinger C, Short B, De Corte V, Bruyneel E, Haas A, Kopajtich R, et al. YSK1 is activated by the Golgi matrix protein GM130 and plays a role in cell migration through its substrate 14-3-3zeta. J Cell Biol 2004;164(7):1009-1020.
21. Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci 2005;118(5):843-846.
22. Sibony M, Segretain D, Gase JM. Angiotensin-converting enzyme in murine testis: step-specific expression of the germinal isoform during spermiogenesis. Biol Reprod 1994;50(5):1015-1026.
23. Ramalho-Santos J, Moreno RD, Wessel GM, Chan EK, Schatten G. Membrane trafficking machinery components associated with the mammalian acrosome during spermiogenesis. Exp Cell Res 2001;267(1):45-60.
24. Perez de Castro I, Bivona TG, Philips MR, Pellicer A. Ras activation in Jurkat T cells following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs only on the Golgi apparatus. Mol Cell Biol 2004;24(8):3485-3496.
25. Gnarra JR, Lerman MI, Zbar B, Linehan WM. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 1995;22(1):3-8.
26. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. Von Hippel-Lindau disease. Lancet 2003;361(9374):2059- 2067.
27. Maher ER. Von Hippel-Lindau disease. Curr Mol Med 2004;4(8):833-842.
28. Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr. Tumour suppression by the human Von Hippel-Lindau gene product. Nat Med 1995;1(8):822-826.
29. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 1996;93(20):10589-10594.
30. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006;20(5): 515-524.
31. Esteban MA, Tran MG, Harten SK, Hill P, Castellanos MC, Chandra A, et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 2006;66(7):3567-3575.
32. Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, Baek JH, et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in Von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 2006;66(5):2725-2731.
33. Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, Ogawa O, et al. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the Von Hippel-Lindau tumor suppressor protein. Am J Pathol 2006;168(2):574-584.
34. Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RS, et al. Induction of hypervascularity without leakage or inflammation in transgenic mice over-expressing hypoxia-inducible factor-1α. Genes Dev 2001;15(19):2520-2532.
35. Vincent KA, Shyu KG, Luo Y, Magner M, Tio RA, Jiang C, et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1α/VP16 hybrid transcription factor. Circulation 2000;102(18):2255-2261.
36. Jiang Y, Zhang W, Kondo K, Klco JM, St Martin TB, Dufault MR, et al. Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL- and hypoxia-dependent pathways. Mol Cancer Res 2003;1(6):453-462.
37. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. Identification of novel hypoxia-dependent and -independent target genes of the Von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 2000;19(54):6297-6305.
38. Craven RA, Hanrahan S, Totty N, Harnden P, Stanley AJ, Maher ER. Proteomic identification of a role for the von Hippel-Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. Proteomics 2006;6(13):3880-3893.
39. Bluyssen HA, Lolkema MP, van Beest M, Boone M, Snijckers CM, Los M, et al. Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Lett 2004;556(1-3):137-142.